Goldman Sachs’s Profound Medical PROF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$121K Sell
18,707
-20
-0.1% -$138 ﹤0.01% 6183
2025
Q4
$147K Buy
18,727
+6,787
+57% +$43.6K ﹤0.01% 6120
2025
Q3
$58.4K Buy
11,940
+345
+3% +$1.76K ﹤0.01% 6154
2025
Q2
$68.4K Buy
+11,595
New +$61.3K ﹤0.01% 5879
2024
Q2
Sell
-16,700
Closed -$142K 5865
2024
Q1
$142K Sell
16,700
-5,500
-25% -$45.9K ﹤0.01% 5190
2023
Q4
$188K Buy
22,200
+2,800
+14% +$26.6K ﹤0.01% 5171
2023
Q3
$198K Buy
19,400
+2,700
+16% +$28K ﹤0.01% 5047
2023
Q2
$217K Buy
+16,700
New +$207K ﹤0.01% 5149

Other funds holding PROF

Goldman Sachs's PROF Position: Q1 2026 in Review

Goldman Sachs reduced its Profound Medical (PROF) stake by 0.11% in Q1 2026, selling an estimated $138 and leaving 18,707 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #6183.

Goldman Sachs first reported a position in PROF in Q2 2023 and has held it in 8 quarters since. The position peaked at $217K in Q2 2023. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Goldman Sachs held 18,707 shares of Profound Medical worth $121K as of Q1 2026.
  • Goldman Sachs sold 20 Profound Medical shares in Q1 2026, an estimated $138.
  • Profound Medical made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6183 holding.
  • Goldman Sachs first reported a position in Profound Medical in Q2 2023 and has held it in 8 quarters since.
  • Goldman Sachs's Profound Medical position peaked at $217K in Q2 2023.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.